Results 281 to 290 of about 86,105 (313)
Some of the next articles are maybe not open access.
Rifampin in the Treatment of Leprosy
Clinical Infectious Diseases, 1983The minimal inhibitory concentration of rifampin for Mycobacterium leprae is less than 1 microgram/ml. Therapy with rifampin has proved efficacious both in mice experimentally infected with M. leprae and in humans with leprosy. Rifampin kills M. leprae more rapidly than do other antileprosy drugs currently available. Consequently, M.
openaire +3 more sources
Inhibition of Cytomegalovirus by Rifampin
Journal of Infectious Diseases, 1972Rifampin at a concentration of 150 gtg/ml interfered with the replication of Davis, Kerr, and AD 169 strains of cytomegalovirus in Wi-38 cells. The replication of herpes-simplex virus (types 1 and 2) and Sindbis virus in the same cells was unaffected by a similar concentration of the antibiotic.
Paul S. Lietman +2 more
openaire +3 more sources
Interaction of Rifampin and Digitoxin
Archives of Internal Medicine, 1983In a patient who had been receiving digitoxin therapy, the serum digitoxin level decreased markedly when rifampin was added to the therapeutic regimen. The serum digitoxin level returned to the pretreatment level when rifampin therapy was discontinued.
Diana M. Poor +2 more
openaire +2 more sources
Archives of Internal Medicine, 1987
To the Editor. —In their recent article, Baciewicz et al 1 presented an excellent update on rifampin drug interactions. There are, however, two therapeutic agents (ethionamide and protionamide) not mentioned that may have serious to potentially fatal consequences when used with rifampin.
openaire +3 more sources
To the Editor. —In their recent article, Baciewicz et al 1 presented an excellent update on rifampin drug interactions. There are, however, two therapeutic agents (ethionamide and protionamide) not mentioned that may have serious to potentially fatal consequences when used with rifampin.
openaire +3 more sources
Clinical Pharmacology and Therapeutics, 1984
Digoxin doses required to maintain therapeutic serum concentrations rose substantially in two patients dependent on dialysis with the commencement of rifampin therapy. When rifampin was discontinued, doses fell to requirements before rifampin. Serum digoxin concentration may fall to ineffective levels with rifampin therapy and rise to potentially toxic
Linda Longerich +3 more
openaire +3 more sources
Digoxin doses required to maintain therapeutic serum concentrations rose substantially in two patients dependent on dialysis with the commencement of rifampin therapy. When rifampin was discontinued, doses fell to requirements before rifampin. Serum digoxin concentration may fall to ineffective levels with rifampin therapy and rise to potentially toxic
Linda Longerich +3 more
openaire +3 more sources
Clinical Infectious Diseases, 1983
Rifampin has proved to be a valuable antibiotic with relatively few major adverse effects. Its toxicity is predominantly hepatic and immunoallergic in character. While hepatic toxicity is dose related and has been observed mainly in patients with underlying liver disease, the immunoallergic effects are usually associated with intermittent or prolonged ...
Stephanie Leventis, Jacques H. Grosset
openaire +3 more sources
Rifampin has proved to be a valuable antibiotic with relatively few major adverse effects. Its toxicity is predominantly hepatic and immunoallergic in character. While hepatic toxicity is dose related and has been observed mainly in patients with underlying liver disease, the immunoallergic effects are usually associated with intermittent or prolonged ...
Stephanie Leventis, Jacques H. Grosset
openaire +3 more sources
Clinical Infectious Diseases, 1983
Rifampin and amphotericin B were found to be synergistic in vitro against Saccharomyces cerevisiae, Histoplasma capsulatum, and several species of Aspergillus, The uptake of rifampin by the fungi was increased in the presence of amphotericin B, and this increase probably formed the basis for the synergistic activity observed.
openaire +3 more sources
Rifampin and amphotericin B were found to be synergistic in vitro against Saccharomyces cerevisiae, Histoplasma capsulatum, and several species of Aspergillus, The uptake of rifampin by the fungi was increased in the presence of amphotericin B, and this increase probably formed the basis for the synergistic activity observed.
openaire +3 more sources
History of the Development of Rifampin [PDF]
Clinical Infectious Diseases, 1983 Rifampin was developed in the Dow-Lepetit Research Laboratories (Milan, Italy) as part of an extensive program of chemical modification of the rifamycins, the natural metabolites of Nocardia mediterranei. One peculiar fact was that all of the studies leading to highly active derivatives were performed on a molecule (rifamycin B) that was itself ...
openaire +2 more sources
Quinidine-Rifampin Interaction
New England Journal of Medicine, 1981DRUG interactions with quinidine are likely to be clinically important, since quinidine is used in the treatment and prophylaxis of potentially serious arrhythmias, and since there is a relatively narrow range between the therapeutic and toxic concentrations.1 An interaction between quinidine and the anticonvulsant drugs primidone and phenobarbital has
Twum-Barima Y, Carruthers Sg
openaire +3 more sources
Archives of Dermatology, 1977
To the Editor.— I was very interested in the letter by Griffiths and Sodeify ( Arch Dermatol 112:1791, 1976) in which rifampin is mentioned as a valuable drug for the treatment of cutaneous leishmaniasis. I would like to report the case of a 19-year-old woman who had a 4 × 4-cm ulcer of eight months' duration on the right forearm.
openaire +2 more sources
To the Editor.— I was very interested in the letter by Griffiths and Sodeify ( Arch Dermatol 112:1791, 1976) in which rifampin is mentioned as a valuable drug for the treatment of cutaneous leishmaniasis. I would like to report the case of a 19-year-old woman who had a 4 × 4-cm ulcer of eight months' duration on the right forearm.
openaire +2 more sources